{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Agent+Asciminib", "query": { "intervention": "Single Agent Asciminib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T21:08:12.675Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03578367", "title": "Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CML", "Chronic Myelogenous Leukemia", "Leukemia, Myeloid Chronic", "Hematologic Diseases" ], "interventions": [ { "name": "Asciminib add-on", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Asciminib 80mg QD (asciminib single agent (ASAC))", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 104, "start_date": "2018-11-22", "completion_date": "2025-02-26", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-09-10T21:08:12.675Z", "location_count": 2, "location_summary": "Augusta, Georgia • Baltimore, Maryland", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03578367" }, { "nct_id": "NCT05143840", "title": "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia, Chronic Phase", "Adult CML", "Leukemia, Myeloid", "Leukemia,Myeloid, Chronic" ], "interventions": [ { "name": "Single Agent Asciminib", "type": "DRUG" }, { "name": "Low TKI", "type": "COMBINATION_PRODUCT" }, { "name": "Elective Free Treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2022-04-22", "completion_date": "2032-02", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-10T21:08:12.675Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05143840" }, { "nct_id": "NCT04877522", "title": "Asciminib Roll-over Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Myelogenous Leukemia", "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" ], "interventions": [ { "name": "Asciminib single agent", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Asciminib single agent pediatric formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "7 Years to 100 Years" }, "enrollment_count": 347, "start_date": "2022-08-30", "completion_date": "2030-08-30", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-10T21:08:12.675Z", "location_count": 6, "location_summary": "Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04877522" }, { "nct_id": "NCT07354074", "title": "Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myelogenous Leukemia", "Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Asciminib single agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 50, "start_date": "2026-04-28", "completion_date": "2033-02-23", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-10T21:08:12.675Z", "location_count": 4, "location_summary": "New Brunswick, New Jersey • New York, New York • Cincinnati, Ohio + 1 more", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07354074" }, { "nct_id": "NCT07136428", "title": "Asciminib in HER2+ Breast Cancer Brain Metastases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2+ Metastatic Breast Cancer" ], "interventions": [ { "name": "Asciminib and Trastuzumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2026-07-07", "completion_date": "2032-11-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-10T21:08:12.675Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07136428" } ] }